Results 71 to 80 of about 56,774 (264)

Homotaurine, a safe blood-brain barrier permeable GABAA-R-specific agonist, ameliorates disease in mouse models of multiple sclerosis. [PDF]

, 2018
There is a need for treatments that can safely promote regulatory lymphocyte responses. T cells express GABA receptors (GABAA-Rs) and GABA administration can inhibit Th1-mediated processes such as type 1 diabetes and rheumatoid arthritis in mouse models.
Dang, Hoa, Kaufman, Daniel L, Olsen, Richard, Tian, Jide, Wallner, Martin   +4 more
core   +3 more sources

Assessing the Relative Importance of Imaging and Serum Biomarkers in Capturing Disability, Cognitive Impairment, and Clinical Progression in Multiple Sclerosis

Advanced Science, EarlyView.
Using machine‐learning analyses in two independent multiple sclerosis cohorts, spinal cord atrophy and cortical degeneration emerged as key predictors of disability and progression independent of relapses. Deep gray matter damage further improved prediction, while serum biomarkers of brain damage provided complementary information, highlighting the ...
Alessandro Cagol, Pascal Benkert, Sabine Schaedelin, Mario Ocampo‐Pineda, Noemi Montobbio, Po‐Jui Lu, Batuhan Ayci, Antonia Wenger, Alfi Aran Shukur, Kornelius Kaim, Lester Melie‐Garcia, Matthias Weigel, Alessio Signori, Pasquale Calabrese, Ludwig Kappos, Maria Pia Sormani, Jens Kuhle, Cristina Granziera   +17 more
wiley   +1 more source

Cognitive impairment in relapsing remitting Multiple Sclerosis [PDF]

Psihološka Obzorja, 2003
The purpose of the study was to identify changes in cognitive abilities that affect patients with relapsing remitting form of multiple sclerosis (MS) and to find out which instrument manifests them best.
Saška Roškar
doaj  

Serum level of brain-derived neurotrophic factor in patients with relapsing–remitting multiple sclerosis: a potential biomarker for disease activity

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021
Background Brain-derived neurotrophic factor (BDNF) is secreted by immune cells in response to neuroimmune and inflammatory cascades as an act to prevent axonal and neuronal damage after various pathological insults. The serum level of BDNF is altered in
Mohammed I. Oraby, Hatem A. El Masry, Sanaa S. Abd El Shafy, Esraa M. Abdul Galil   +3 more
doaj   +1 more source

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. [PDF]

, 2018
BackgroundNo evidence of disease activity (NEDA; defined as no 12-week confirmed disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions) using a fixed-study entry baseline is commonly used
Arnold, Douglas L, Bar-Or, Amit, Belachew, Shibeshih, Bennett, Iain, Buffels, Regine, Comi, Giancarlo, Garren, Hideki, Giovannoni, Gavin, Han, Jian, Hartung, Hans-Peter, Hauser, Stephen L, Havrdová, Eva, Julian, Laura, Kappos, Ludwig, Lublin, Fred, Napieralski, Julie, Selmaj, Krzysztof, Traboulsee, Anthony   +17 more
core   +1 more source

Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases

Advanced Science, EarlyView.
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo, Lanjie Lei, Ying Jin, Lan Su, Shumao Cui, Liyun Shi   +5 more
wiley   +1 more source

A double‐blind, randomized, placebo‐controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing‐remitting multiple sclerosis

Annals of Clinical and Translational Neurology, 2022
Objective Inhibition of dihydroorotate dehydrogenase suppresses magnetic resonance imaging brain lesions and disease activity in multiple sclerosis but has limiting tolerability.
Robert J. Fox, Heinz Wiendl, Christian Wolf, Nicola De Stefano, Johann Sellner, Viktoriia Gryb, Konrad Rejdak, Plamen Stoyanov Bozhinov, Nataliya Tomakh, Iryna Skrypchenko, Andreas R. Muehler   +10 more
doaj   +1 more source

Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence

Annals of Neurology, EarlyView.
Objective The objective of this study was to compare the long‐term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS). Methods Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from
Gabriel Cerono, Bruce A.C. Cree, Stephen L. Hauser, Sergio E. Baranzini   +3 more
wiley   +1 more source

Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. [PDF]

PLoS ONE, 2014
For almost three decades in many countries azathioprine has been used to treat relapsing-remitting multiple sclerosis. However its efficacy was usually considered marginal and following approval of β interferons for this indication it was no longer ...
Luca Massacesi, Irene Tramacere, Salvatore Amoroso, Mario A Battaglia, Maria Donata Benedetti, Graziella Filippini, Loredana La Mantia, Anna Repice, Alessandra Solari, Gioacchino Tedeschi, Clara Milanese   +10 more
doaj   +1 more source

The Pathogenesis Of Primary Progressive Multiple Sclerosis: Antibody-Mediated Attack And No Repair? [PDF]

, 2004
Primary progressive multiple sclerosis (MS) differs from the more common form of MS which has an initial relapsing-remitting course in a number of ways, including pathological features, clinical course, differential diagnosis and response to treatment ...
Pender, Michael P.
core   +1 more source